Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
  • A61K40/22—Immunosuppressive or immunotolerising
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
  • A61K40/31—Chimeric antigen receptors [CAR]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/418—Antigens related to induction of tolerance to non-self
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
  • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
  • A61K40/421—Immunoglobulin superfamily
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
  • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
  • A61K40/421—Immunoglobulin superfamily
  • A61K40/4211—CD19 or B4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/70503—Immunoglobulin superfamily
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/70503—Immunoglobulin superfamily
  • C07K14/7051—T-cell receptor (TcR)-CD3 complex
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
  • C12N5/0636—T lymphocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
  • A61K2039/507—Comprising a combination of two or more separate antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
  • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/54—F(ab')2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/55—Fab or Fab'
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
  • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
  • C07K2317/622—Single chain antibody (scFv)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/75—Agonist effect on antigen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
  • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
  • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2510/00—Genetically modified cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
  • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

• 3314070AWO_SequenceListing_ST25.txt is 104 kilobytes in size.
• the file is hereby incorporated by reference in its entirety into the present application.
• the present disclosure relates generally to antigen-binding proteins involved in immune function. More particularly, the present disclosure relates to recombinant antibodies, chimeric antigen receptors and fragments thereof with specificity for PD-1 .
• the goal of cancer immunotherapy is to treat malignant disease by modulating cancer specific immune responses.
• a prime target is the programmed cell death (PD-1 ) receptor, which is expressed on the surface of activated T cells and leads to an intracellular inhibitory signal when bound to one of its ligands, PD-L1 and PD-L2.
• PD-1 programmed cell death
• PD-1 has been shown to play a role in cancer.
• expression of PD-1 and/or PD-L1 has been found in a number of primary tumor biopsies assessed by immunohistochemistry.
• Such tissues include cancers of the lung, liver, ovary, cervix, skin, colon, glioma, bladder, breast, kidney, esophagus, stomach, oral squamous cell, urothelial cell, and pancreas as well as tumors of the head and neck.
• PD-ligand expression on tumor cells has been correlated to poor prognosis of cancer patients across multiple tumor types.
• antigen-binding proteins such as antibodies and chimeric antigen receptors that are able to specifically bind a protein receptor associated with programmed cell death, PD-1 , on T cells, thereby modulating immune response by the T cells.
• PD-1 programmed cell death
• PD-L1 blockade of the PD-1 signaling pathway inhibits apoptosis of the T cells.
• the disclosure relates to recombinant antigen- binding proteins, antibodies and chimeric antigen receptors or antigen-binding portions thereof that bind specifically to PD-1 and prevent binding of its ligand.
• the disclosure relates to a recombinant antigen-binding protein or antigen-binding fragment thereof comprising one of: (A) an antigen binding region having an amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 21 , SEQ ID NO: 32, SEQ ID NO: 43, SEQ ID NO: 53, SEQ ID NO: 61 , SEQ ID NO: 72, SEQ ID NO: 83, SEQ ID NO: 94, SEQ ID NO: 103, SEQ ID NO: 1 14, SEQ ID NO: 125, SEQ ID NO: 133, SEQ ID NO: 142; a fragment thereof, and a homologous sequence thereof;
• LC light chain
• LCCDR light chain complementarity determining regions
• HC heavy chain
• HCCDR heavy chain complementarity determining regions
• a light chain comprising LCCDR1 , LCCDR2 and LCCDR3 respectively, having the amino acid sequence SSNIGAGYA (SEQ ID NO: 12), TNN and QSYDSSLSGVI (SEQ ID NO: 13) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GYTLTELS (SEQ ID NO: 14), FDPEDGET (SEQ ID NO. 15) and ARAYYGFDQ (SEQ ID NO: 16); fragments thereof or homologous sequences thereof;
• LC light chain
• LC light chain
• ARWYSSYYDV (SEQ ID NO: 38); fragments thereof or homologous sequences thereof;
• LC light chain
• NIGSKS amino acid sequence NIGSKS (SEQ ID NO: 34), YDS and QVWDSSSDYV (SEQ ID NO: 45) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), ISGSGGST (SEQ ID NO. 47) and
• ARNYISMFDS SEQ ID NO: 48; fragments thereof or homologous sequences thereof; (vi) a light chain (LC) comprising LCCDR1 , LCCDR2 and LCCDR3
• NIGSKS amino acid sequence NIGSKS (SEQ ID NO: 34), YDS and QVWDSSSDHV (SEQ ID NO: 55) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), ISGSGGST (SEQ ID NO. 47) and
• ARGYSSYYDA (SEQ ID NO: 56); fragments thereof or homologous sequences thereof;
• LC light chain
• a light chain comprising LCCDR1 , LCCDR2 and LCCDR3 respectively, having the amino acid sequence RSNIGSNT (SEQ ID NO: 74), NNN and ATWDDSLNEYV (SEQ ID NO: 75) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GYTFTRYG (SEQ ID NO: 76), ISGYNGNT (SEQ ID NO. 77) and ARHGYGYHGD (SEQ ID NO: 78); fragments thereof or homologous sequences thereof;
• LC light chain
• LC light chain
• NIGDKS amino acid sequence 96
• YDS and QVWASGTDHPYVI amino acid sequence 97
• HC heavy chain comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), ISGSGGST (SEQ ID NO. 47) and
• ARMYGSYTDM (SEQ ID NO: 98); and a fragment or homologous sequence thereof;
• LC light chain
• LC light chain
• ARGDVTYDE (SEQ ID NO: 120); fragments thereof or homologous
• LC light chain
• NIGSKS amino acid sequence NIGSKS (SEQ ID NO: 34), YDD and QVWDINDHYV (SEQ ID NO: 127) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), ISGSGGST (SEQ ID NO. 47) and
• ARSQASFMDI (SEQ ID NO: 128); fragments thereof or homologous sequences thereof; or
• LC light chain
• HC heavy chain
• ARGTGYDGDQ (SEQ ID NO: 137) and fragments thereof or homologous sequences thereof.
• the recombinant antigen-binding protein or antigen-binding fragment thereof comprises a fragment of at least one of the recited SEQ ID NOS that is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the entire length of the at least one recited SEQ ID NO.
• the recombinant antigen-binding protein or antigen-binding fragment thereof comprises a sequence homologous to at least one of the recited SEQ ID NOS that has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity to the at least one recited SEQ ID NO.
• the disclosure relates to recombinant antigen- binding proteins or antigen-binding fragments thereof, wherein the
• recombinant antigen-binding protein is an antibody, chimeric antigen receptor (CAR), fusion protein or conjugate thereof.
• CAR chimeric antigen receptor
• the recombinant antigen-binding protein is an antibody, chimeric antigen receptor (CAR), fusion protein or conjugate thereof.
• recombinant antigen-binding protein or antigen-binding fragment thereof is conjugated to a therapeutic agent, for example, a drug, toxin or cytotoxic moiety, radioisotope, protein or peptide.
• a therapeutic agent for example, a drug, toxin or cytotoxic moiety, radioisotope, protein or peptide.
• An antibody of the disclosure is a full-length antibody, an intact antibody, fragments and homologous sequences thereof, including but not limited to, an Fab fragment, an F(ab')2 fragment or a single chain variable fragment (scFv).
• the antigen-binding region specifically binds to an epitope of human PD-1 and blocks binding of PD-1 to its ligand(s).
• the disclosure relates to nucleic acids encoding an antigen-binding protein of the disclosure as well as vectors and cells comprising such nucleic acids or antigen-binding proteins.
• the disclosure relates to a method of increasing a T cell response in a subject comprising administering a therapeutically effective amount of an antigen-binding protein or an antigen binding fragment thereof.
• the administration of a therapeutically effective amount of the antigen-binding protein or antigen binding fragment thereof inhibits, reduces, modulates or abolishes signal transduction mediated by PD-1 .
• the disclosure relates to a method for treatment of a subject having a PD1 -positive disease comprising administering to the subject a therapeutically effective amount of an antigen-binding protein or antigen binding fragment thereof.
• a pharmaceutical composition comprising the antigen-binding protein or antigen binding fragment thereof is administered.
• the disclosure relates to a vector comprising a nucleic acid encoding a recombinant anti-PD-1 antigen- binding protein and a nucleic acid encoding a chimeric antigen receptor, wherein said recombinant anti-PD-1 antigen-binding protein is not identical to said chimeric antigen receptor.
• the disclosure relates to a cell comprising the vector described herein.
• the disclosure relates to a cell comprising a nucleic acid encoding a recombinant anti-PD-1 antigen- binding protein and a nucleic acid encoding a chimeric antigen receptor, wherein said recombinant anti-PD-1 antigen-binding protein is not identical to said chimeric antigen receptor.
• the disclosure relates to a cell comprising a recombinant anti-PD-1 antigen-binding protein and a chimeric antigen receptor, wherein said recombinant anti-PD- 1 antigen-binding protein is not identical to said chimeric antigen receptor.
• the chimeric antigen receptor does not specifically bind to PD-1 .
• the disclosure provides a method of increasing a T cell response in a subject comprising administering to the subject a therapeutically effective amount of a recombinant anti-PD-1 antigen-binding protein, a vector, a cell, or a pharmaceutical composition described herein, wherein the recombinant anti-PD-1 antigen-binding protein is a PD-1 antagonist.
• the disclosure provides a method of decreasing a T cell response in a subject comprising administering to the subject a therapeutically effective amount of a recombinant anti-PD-1 antigen-binding protein, a vector, a cell, or a pharmaceutical composition described herein, wherein the recombinant anti-PD-1 antigen-binding protein is a PD-1 agonist.
• the disclosure provides a method for treatment of a subject having a PD1 -positive disease, comprising
• a recombinant anti-PD-1 antigen-binding protein a vector, a cell, or a pharmaceutical composition described herein.
• the disclosure provides a method for treatment of a subject having a PD1 -positive disease, comprising transducing at least one T cell of the subject with a nucleic acid encoding a recombinant anti-PD-1 antigen-binding protein and a nucleic acid encoding a chimeric antigen receptor, wherein said recombinant anti-PD-1 antigen-binding protein is not identical to said chimeric antigen receptor.
• the chimeric antigen receptor does not specifically bind to PD-1 .
• the PD1 -positive disease is a cancer.
• the PD1 - positive disease is an autoimmune disease.
• Figure 1 shows relative binding affinity of scFv-Fc clones to PD- 1 monomer.
• Figures 2A and B show disruption of the interaction of PD-1 with its ligand, PD-L1. A.
• FIG. 1 is a schematic of the competitive binding assay used to measure the ability of the scFv-Fc to disrupt the PD-1/PD-L1 interaction.
• (1 ) biotinylated PD-1 -Fc was mixed with serially diluted ET901 ScFv-Fc (negative control) or anti-PD1 ScFv-Fcs; and (2) then added into a PD-L1 -Fc coated plate.
• step (3) PD-1 -Fc binding towards coated PD-L1 was visualized via HRP-conjugated streptavidin.
• FIG. 3 is a schematic of the construct used.
• a secreteable scFv was designed to include a murine kappa leader sequence to allow exportation of the scFv from the cell.
• a serine glycine linker (G4S) was used to link the variable heavy chain and variable light chain.
• a HIS/HA tag was included to allow detection of the scFv.
• SFG-1928z/scFv retroviral construct depicting the 5' and 3' long terminal repeats (LTR), splice donor (SD), splice acceptor (SA), packaging element ( ⁇ ), CD8 leader sequence (CD8), variable heavy (VH) and variable light (VL) chains of the single chain variable fragment (scFv), transmembrane domain (TM), human CD28 signaling domain (hCD28), human zeta chain signaling domain ( ⁇ chain) and position of the anti-PD-1 scFv.
• LTR 5' and 3' long terminal repeats
• SD splice donor
• SA splice acceptor
• ⁇ packaging element
• CD8 leader sequence CD8 leader sequence
• VH variable heavy
• VL variable light chains of the single chain variable fragment
• TM transmembrane domain
• hCD28 human CD28 signaling domain
• ⁇ chain human zeta chain signaling domain
• FIG. 4 Expansion of human peripheral blood T cells modified to express the 1928z CAR alone or with a PD-1 scFv.
• Transduced T cells were cultured in 50 lU/ml recombinant human IL-2 and expansion was monitored.
• T cells modified to express the CAR and secrete anti-PD-1 scFv clone 23 or 27 had expansion that was at least equivalent to T cells expressing the CAR alone.
• Cells modified to express the 1928z CAR and secrete anti-PD-1 scFv clones 16, 18, 26, 31 or 40 did not expand in vitro. Data shown is representative of two independent experiments.
• FIG. 5 INF- ⁇ secretion (pg/ml) from tumor targeted T cells that secrete an anti-PD-1 scFv.
• T cells expressing the CAR or CAR and secreting an anti-PD-1 scFv were cocultured with CD19+ Raji tumor cells. Supernatants were analysed with Luminex technology to detect the levels of cytokines secreted from the T cells.
• T cells modified to express the 1928z CAR and secrete anti-PD-1 scFv clones 23 and 27 had increased secretion of IFN- ⁇ compared to cells modified to express the CAR alone.
• Figure 6 shows the results of transduction of human T cells with 1928z CAR and Eureka anti-PD-1 scFvs. (Upper panel) Following
• Figure 7 shows the effect of the presence of anti-PD-1 scFv in T cells modified to express the 1928z CAR and Eureka anti-PD-1 scFv.
• Human T cells transduced to express the CAR and the Eureka anti-PD-1 scFvs were incubated with golgi inhibitors for 4 hours prior to preparation of western blot lysates.
• Western blot analysis was used to detect anti-PD-1 scFv by probing the membrane with anti-HA antibody. Membranes were probed with anti- GAPDH antibody as loading control.
• FIG 8 shows the expansion of human T cells modified to express the 1928z CAR and anti-PD-1 scFv in the presence/absence of PD- L1/L2.
• Human T cells modified to express the CAR and secrete anti-PD-1 scFv clones 23, 26, 27, and 40 were placed on artificial antigen presenting cells (aAPCs, murine 3T3 fibroblasts) expressing human PD-1 L1/L2 or not. After 24 hours incubation with aAPCs, CD3/CD28 activating beads were added to the cells to stimulate proliferation (1 :2 bead:T cell ratio). After 3 days, T cells were enumerated using trypan blue exclusion.
• aAPCs artificial antigen presenting cells
• T cells modified to express the 1928zCAR and anti-PD-1 scFv clone 26 and 23 had decreased proliferation on aAPCs expressing PD-L1/L2 to aAPCs not expressing inhibitory ligands.
• T cells modified to express the 1928zCAR and anti-PD-1 scFv clone 27 had increased expansion on aAPCs expressing PD- L1/L2. Data shown is representative of one experiment.
• Figure 9 shows the amino acid sequences for the complementarity determining regions (CDR) for light and heavy variable chains of some antigen-binding proteins of the disclosure.
• FIG. 10 shows that monoclonal antibodies generated from the anti- PD-1 specific scFvs bind to PD-1 on human T cells.
• Human monoclonal antibodies from the PD-1 specific scFvs were generated and incubated with human T cells modified to overexpress human PD-1 (1 pg/ml). Flow cytometry was used to detect bound antibody using a goat anti-human Ig FITC conjugated antibody.
• Clones 23, 26 and 27 monoclonal antibodies bound P-1 human T cells at 51 %, 78% and 67% respectively. Control antibody (clone 901 ) did not bind human PD-1 on T cells. Data shown is representative of one experiment.
• FIG 11 shows that T cells modified to express a first generation CAR incubated on aAPCs expressing PD-L1/L2 expand when anti-PD-1 clone 27 monoclonal antibody is present.
• Human T cells modified to express the first generation CD19-specific CAR (19z1 ) were incubated with anti-PD-1 monoclonal antibodies for 24 hours then placed on aAPCs expressing PD- L1/L2 or not. After 24 hours stimulation with aAPCs, the cells were then stimulated with CD3/CD28 beads. After three days, the cells were
• FIGS 12A-12D show the generation of CAR T cells further modified to secrete PD-1 blocking scFv, E27.
• A. Bicistronic retroviral constructs were generated encoding a CD19-specific CAR (termed 1928z) or an ovarian tumor antigen specific CAR (termed 4H1 128z) and the PD-1 blocking scFv, E27. The E27 was preceded by a signal peptide, mouse IgK, to allow secretion of the scFv. A HA/His tag was also included to detect the scFv once secreted from the T cells.
• Human peripheral blood T cells were transduced with the retroviral constructs encoding the CAR, 1928z, or the CAR and the E27 PD-1 blocking scFv, 1928z-E27. Following transduction, flow cytometry was used to detect expression of the CAR, using an antibody that specifically binds the CD19-targeted CAR, termed 19E3.
• C Western blot analysis of supernatant from transduced human T cells was utilized to detect the PD-1 blocking scFv with an anti-HA antibody.
• D
• CAR T cells expressing either the CAR alone (1928z or 4H1 128z control CAR), the CAR and the E27 scFv (1928z-E27 or 4H1 128z-E27), or the CAR and a control scFv (1928z-B6H12.2 or 4H1 128z-B6H12.2) were incubated with 51 Cr labeled tumor cells (Raji or Nalm6) for 4 hrs.
• T cells expressing the CD19 specific CAR were able to lyse the tumor targets at equivalent levels, and the ovarian-targeted CAR T cells were unable to lyse Raji or Nalm6.
• FIGS 13A-13D show that T cells modified to express the CAR and secrete a PD-1 blocking scFv resist inhibition from PD-L1 -PD-1 interactions, in vitro.
• 1928z-E27 cells (upper curves) continued to expand to greater levels compared to 1928z T cells (lower curves) when cultured with PDL1 + tumor cells.
• 1928z-E27 retained ability to lyse PD-L1 tumor targets upon re-stimulation compared to 1928z cells.
• Figure 14 shows in vivo anti-tumor efficacy of T cells modified to express the CAR and secrete the PD-1 blocking scFv.
• Figures 15A-15D relate to the selection of PD-1 blocking scFv, E27.
• a PD-1 blocking mAb candidates E27, E26 and E23 were used in a competitive binding assay to detect interruption of PD-1 binding to PD-L1 at varying concentrations, compared to a control mAb, targeted to a hapten not present in humans.
• E23, E26 and E27 mAbs all prevented PD-1 binding to PD-L1 .
• B Schematic of design of PD-1 blocking scFv designed from the E23, E26 and E27 mAbs used in A, where the signal peptide was linked to the variable heavy sequence and a serine glycine linker and the the variable light sequence.
• This HIS/HA tag was included for detection of the scFv.
• C Western blot on SN from 293Glv9 packaging cells transduced to express the secretable scFvs with the 1928z CAR, stained with anti-HA antibody. The E27 scFv was detected at the highest levels and therefore was used in the remainder of the publication.
• D Western blot on SN from PBMCs + 4H1 128z and PBMCs +4H1 128z stained with anti-HA mAb.
• FIGS 16A-16E show that T cells can be co-modified to express CAR and secrete PD-1 blocking scFv, E27.
• a Raji tumor cells were retrovirally modified to express human PD-L1 (Raji-PDL1 ) and were stained with mAb specific for PD-L1 .
• Parental Raji tumor (Raji) express no PD-L1 and Raji-PDL1 tumor cells expressed high levels of PD-L1 .
• B Representative flow cytometry plots showing1928z-E27 T cells lyse more Raji-PDL1 tumor cells compared to 1928z T cells as determined with flow cytometry following 72 hrs co-culture.
• 1928z-E27 T cells expand to greater numbers following co-culture with Raji- PDL1 tumor cells as determined by flow cytometry and enumeration beads, data shown is the average total number of T cells +/- SEM from 4 independent experiments.
• F 1928z T cells express significantly more PD-1 compared to 1928z-E27 T cells, with regard to percentage positive cells and mean fluorescence intensity (MFI) of PD-1 staining. Data show in the mean +/- SEM from 4 independent experiments.
• MFI mean fluorescence intensity
• FIGS 18A-18C show that E27 protects proliferative capacity of CD3/CD28 stimulated T cells in the context of PD-L1 .
• a NIH3T3 cells were retrovirally modified to express human PD-L1 (3T3-PDL1 ) and were stained with mAb specific for PD-L1 .
• Parental NIH3T3 (3T3-EMPTY) express no PD- L1 and 3T3-PDL1 tumor cells expressed high levels of PD-L1 .
• B 1928z and 1928z-E27 T cells were cultured with 3T3-EMPTY or 3T3-PDL1 cells and stimulated with CD3/CD28 beads.
• FIG. 19 shows that CAR T cells secreting E27 scFv have increased anti-tumor function in vivo.
• SCID-Beige mice were inoculated with Raji-PDL1 tumor cells intravenously, and the following day were infused intravenously with CAR T cells.
• Mice treated with 1928z-E27 T cells had enhanced survival compared to mice treated with 1928z T cells.
• Mice treated with 1928z T cells survived longer than untreated mice, and mice treated with CAR T cells targeted to an irrelevant antigen, 4H1 128z and 4H1 128z-E27 T cells. Data shown is from 2 independent experiments.
• Figure 20 shows the results of a PD1/PDL1 blocking ELISA using the anti-PD-1 antibodies, ET130-23, ET130-26 and ET130-27.
• ET901 negative control
• Figure 21 shows the results of a PD1/PDL2 blocking ELISA using the anti-PD-1 antibodies, ET130-23, ET130-26 and ET130-27.
• ET901 negative control
• ET901 showed no binding
• ET130-23, ET130-26 and ET130-27 showed a blocking effect to PD1/PDL1 binding over a range of concentrations between 0.031 and 10 pg/ml.
• Figure 21 shows the results of a PD1/PDL2 blocking ELISA using the anti-PD-1 antibodies, ET130-23, ET130-26 and ET130-27.
• ET901 negative control
• ET130-23, ET130-26 and ET130-27 showed a blocking effect to PD1/PDL1 binding over a range of concentrations between 0.031 and 10 ⁇ / ⁇ .
• an "antigen-binding protein” is a protein or polypeptide that comprises an antigen-binding region or antigen-binding portion, that is, has a strong affinity to another molecule to which it binds.
• Antigen-binding proteins encompass antibodies, chimeric antigen receptors and fusion proteins.
• Antibody and “antibodies” as those terms are known in the art refer to antigen binding proteins of the immune system.
• the term “antibody” as referred to herein includes whole, full length antibodies and any fragment thereof in which the "antigen-binding portion” or “antigen-binding region” is retained, or single chains thereof.
• a naturally occurring “antibody” is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant (CH) region.
• VH heavy chain variable region
• CH heavy chain constant region
• Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant CL region.
• the light chain constant region is comprised of one domain, CL.
• the VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
• CDR complementarity determining regions
• FR framework regions
• Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
• the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
• the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C
• antigen-binding portion or "antigen-binding region” of an antibody, as used herein, refers to that region or portion of the antibody that confers antigen specificity; fragments of antigen-binding proteins, for example, antibodies therefore, includes one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., an HLA-peptide complex). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
• antigen-binding fragments encompassed within the term "antibody fragments" of an antibody include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a Fab fragment (Ward et al., 1989 Nature 341 :544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR).
• Fab fragment a monovalent fragment consisting of the VL, VH, CL and CH1 domains
• F(ab)2 fragment a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region
• Fd fragment consisting of the VH and CH1 domains
• single chain Fv single chain Fv
• scFv single chain Fv
• Bird et al. 1988 Science 242:423-426
• Huston et al. 1988 Proc. Natl. Acad. Sci. 85:5879-5883.
• single chain antibodies are also intended to be
• antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.
• a “recombinant antibody” or “recombinant antigen-binding protein” is one which has an antigen binding portion that has been identified and selected based on binding characteristics for inclusion in a recombinantly generated antigen-binding protein, for example an antibody.
• homologous sequence thereof refers to amino acid and nucleotide sequences that are between 60 and 99.9% identical to the sequences shown in Tables 1 -14.
• a homologous sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity.
• a homologous sequence has 95-99.9% identity; in another embodiment the homologous sequence has 98-99.9%.
• scFv single chain variable fragments that specifically bind to human PD-1 were selected and tested.
• scFvs were isolated from a phage display library that is a proprietary fully human antibody scFv phage library (Eureka Therapeutics, Emeryville CA).
• the library is composed of human antibody repertoires from more than 100 Caucasian and Asian healthy donors, and from donors with autoimmune disease, such as systemic lupus erythematosus, scleroderma, etc.
• the antigen used for antibody phage panning was a recombinant fusion protein, PD-1 extracellular domain fused to human lgG1 Fc (PD-1 ECD-Fc domain.
• DNA sequences encoding PD-1 ECD and hlgG1 Fc were
• PD-1 ECD-Fc fusion protein was purified by standard FPLC method from HEK293 cell culture medium after the cells died off.
• a human scFv antibody phage display library is used for the selection of mAb clones.
• biotinylated antigens PD-1 ECD-Fc fusion protein
• the antigen-scFv antibody complexes can be pulled down by streptavidin-conjugated
• Panning can be performed for 3-4 cycles to enrich scFv phage clones that bind to PD-1 specifically.
• Positive clones can be determined by standard ELISA method against biotinylated single chain PD-1 .
• Positive clones can be further tested for their binding to PD-1 on live cell surfaces by flow cytometry, using a PD-1 + cell line, for example a 3T3 cell line.
• VL variable light
• VH variable heavy chain amino acid sequences and the nucleotide sequences that code for these embodiments are shown in Tables 1 -14 below.
• the VL and VH sequences were linked with a serine glycine linker to form an scFv.
• a HA/His tag can be included to allow for detection of the scFv.
• the disclosure includes anti-bodies that have the scFv sequence fused to one or more constant domains of the heavy chain to form an antibody with an Fc region of a human immunoglobulin to yield a bivalent protein, increasing the overall avididty and stability of the antibody.
• the Fc portion allows the direct conjugation of other molecules, including but not limited to fluorescent dyes, cytotoxins, radioisotopes etc. to the antibody for example, for use in antigen quantitation studies, to immobilize the antibody for affinity measurements, for targeted delivery of a therapeutic agent, to test for Fc-mediated cytotoxicity using immune effector cells and many other applications.
• the anti-PD-1 antigen-binding proteins may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding, expression levels or to introduce a site for conjugation of therapeutic agents. These scFv are then used to produce recombinant human monoclonal Igs in accordance with methods known to those of skill in the art.
• the antigen-binding protein is a chimeric antigen receptor (CAR).
• CAR-T therapy is a new form of targeted immunotherapy. It merges the extraordinary specificity of monoclonal antibodies with the potent cytotoxicity and long-term persistence provided by cytotoxic T cells. This technology enables T cells to acquire long-term novel antigenic specificity independent of the endogenous TCR.
• Clinical trials have shown clinically significant antitumor activity of CAR-T therapy in neuroblastoma (Louis C.U. et ai, Blood 118(23):6050-6056), B-ALL (Maude S.L. et al., N. Engl. J. Med.
• the chimeric antigen receptor comprises an extracellular domain comprising the antibody moiety, a transmembrane domain, and an intracellular signaling domain.
• the intracellular signaling domain comprises a ⁇ 3 ⁇ intracellular signaling sequence and a co-stimulatory signaling sequence.
• the co-stimulatory signaling sequence is a CD28 intracellular signaling sequence.
• aspects of the disclosure include without limitation, the use of antigen-binding proteins and nucleic acids that encode them for treatment of PD1 associated disease, for diagnostic and prognostic applications as well as use as research tools for the detection of PD1 in cells and tissues.
• compositions comprising the disclosed antigen-binding proteins and nucleic acids are encompassed by the disclosure.
• Vectors comprising the nucleic acids of the disclosure for antibody-based treatment by vectored immunotherapy are also contemplated by the present disclosure.
• Vectors include expression vectors which enable the expression and secretion of antibodies, as well as vectors which are directed to cell surface expression of the antigen binding proteins, such as chimeric antigen receptors (CAR).
• CAR chimeric antigen receptors
• kits that contain a PD1 antibody or nucleic acids of the disclosure, assay reagents, buffers, and the like.
• the heavy and light chains of an antibody of the disclosure may be full-length (e.g., an antibody can include at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains) or may include an antigen-binding portion (a Fab, F(ab')2, Fv or a single chain Fv fragment ("scFv")).
• the antibody heavy chain constant region is chosen from, e.g., lgG1 , lgG2, lgG3, lgG4, IgM, lgA1 , lgA2, IgD, and IgE.
• the immunoglobulin isotype is selected from lgG1 , lgG2, lgG3, and lgG4, more particularly, lgG1 (e.g., human lgG1 ).
• lgG1 e.g., human lgG1
• the choice of antibody type will depend on the immune effector function that the antibody is designed to elicit.
• Nucleic acids that encode the antigen binding proteins identified herein can be used to engineer recombinant immune effector cells.
• Methods and vectors to generate genetically modified T-cells, for example, are known in the art (See Brentjens et al., Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias in Blood 1 18(18):4817-4828, November 201 1 ).
• inventions of the disclosure include cells and expression vectors comprising nucleic acids encoding the antigen-binding proteins or antigen-binding fragments thereof of the disclosure.
• the cells may be recombinant immune effector cells, such as T-cells genetically modified to express a chimeric antigen receptor comprising an antigen binding region in accordance with the present disclosure.
• Cells which have been engineered to produce antibodies in accordance with the disclosure are also encompassed by the disclosure.
• the disclosure comprises a method of producing an antibody or antibody fragment of the disclosure comprising: (a) culturing the recombinant cell comprising a nucleic acid encoding an antibody or antibody fragment of the disclosure in culture medium under conditions wherein the nucleic acid sequence is expressed, thereby producing polypeptides comprising the light and heavy chain variable regions; and (b) recovering the polypeptides from the host cell or culture medium.
• antigen-binding protein of the disclosure encompass antagonistic anti-PD1 antibodies as well as anti-PD1 antibodies that function as agonists of PD1 . While some anti-PD1 antibodies are antagonists, that is, they block binding of PD1 by its ligand, others are agonists, antibodies that have the effect of enhancing the immunosuppressive signal of PD-1 , making them useful in the treatment of autoimmunity, for example. Antibodies of the disclosure that exhibit antagonist activity include clones 23 and 27 while clones 16, 18, 26, 31 and 40 appear to function as agonists.
• the disclosure also comprises the use of an anti-PD-1 antibody or antibody fragment of the disclosure for the preparation of a medicament to increase immune response as well as the use of an anti-PD-1 antibody or antibody fragment of the disclosure for the preparation of a medicament to treat cancer.
• Pharmaceutical compositions comprising the antigen binding protein, antibodies, nucleic acids, vectors or cells comprising the nucleic acids or antigen binding proteins of disclosed herein along with a pharmaceutically acceptable carrier are also encompassed by the disclosure.
• the disclosure also comprises the use of an anti-PD-1 antibody or antibody fragment of the disclosure as a vaccine adjuvant.
• the disclosure relates to an immunoconjugate comprising a first component which is an antigen-binding protein, antibody or antigen-binding fragment thereof as disclosed herein.
• the immunoconjugate comprises a second component that is a cytotoxin, a detectable label, a radioisotope, a therapeutic agent, a binding protein or a molecule having a second amino acid sequence.
• the second component is a binding protein or second antibody
• the binding protein or second antibody has binding specificity for a target that is different from the HLA-peptide complex for which the first is specific.
• the disclosure also relates to methods for treatment of a subject having a PD-1 associated disease, comprising administering to the subject a therapeutically effective amount of an antigen binding protein, antibody or antigen binding fragment thereof, a chimeric antigen receptor (CAR), a nucleic acid encoding the antigen binding protein or a cell comprising the nucleic acids or proteins as disclosed herein.
• CAR chimeric antigen receptor
• scFv-Fc domain fusion proteins were generated, where the scFvs were linked to a murine Fc (mouse IgGI a) domain.
• the scFv-Fc clones were then analyzed for the ability to bind PD-1 by coating an ELISA plate with human PD-1 monomer. Binding of the scFvs to PD-1 was quantified using a HRP- conjugated anti-mouse lgG1 Fc secondary antibody. All seven antibodies showed binding activity with respect to the PD1 monomer in a dose dependent manner ( Figure 1 ).
• Human T cells modified to express the 1928 CAR and a PD-1 blocking scFv were analyzed by flow cytometry. Following verification of expression of the CAR ( Figure 6) the presence of the scFvs was determined using western blot (using an antibody specific for an HA tag incorporated in the scFv design) on lysates prepared from human T cells treated with golgi inhibitors to allow detection in the cell lysates. Human T cells modified to express 1928z CAR and clone 23 had significantly less scFv protein compared to the other clones (Figure 7).
• 3T3 murine fibroblasts artificial antigen presenting cells, a APCs
• CD3/D28 beads were added to the cultures to activate the human T cells.
• T cells modified to express the 1928z CAR and anti-PD-1 scFv clone 26 and 23 have decreased proliferation on aAPCs expressing PD-L1/L2 to aAPCs not expressing inhibitory ligands (Figure 8).
• T cells modified to express the 1928z CAR and anti-PD-1 scFv clone 27 have increased expansion on aAPCs expressing PD-L1/L2.
• T cells modified to express a first generation CAR incubated on aAPCs expressing PD-L1/L2 expand when anti-PD-1 clone 27 monoclonal antibody is present.
• Human T cells modified to express the first generation CD19-specific CAR (19z1 ) were incubated with anti-PD-1 monoclonal antibodies for 24 hours then placed on aAPCs expressing PD-L1/L2 or not. After 24 hours stimulation with aAPCs, the cells were then stimulated with CD3/CD28 beads. After three days, the cells were enumerated.
• CAR T cells further modified to secrete PD-1 blocking scFv, E27.
• Bicistronic retroviral constructs were generated encoding a CD 19- specific CAR (termed 1928z) or an ovarian tumor antigen specific CAR
• CAR T cells expressing either the CAR alone (1928z or 4H1 128z control CAR), the CAR and the E27 scFv (1928z-E27 or 4H1 128z- E27), or the CAR and a control scFv (1928z-B6H12.2 or 4H1 128z-B6H12.2) were incubated with 51 Cr labeled tumor cells (Raji or Nalm6) for 4 hrs.
• T cells expressing the CD19 specific CAR were able to lyse the tumor targets at equivalent levels, and the ovarian-targeted CAR T cells were unable to lyse Raji or Nalm6 ( Figure 12D). Therefore, we conclude that secretion of the scFv did not interrupt the ability of the CAR to redirect T cell lytic capacity.
• T cells modified to express the CAR and secrete a PD-1 blocking scFv resist inhibition from PD-L1 -PD-1 interactions in vitro.
• T cells expressing the CAR alone (1928z), or the CAR and the PD-1 blocking scFv (1928z-E27) were cultured on 3T3 cells empty cells or 3T3 cells modified to express human PD- L1 .
• 3T3 feeder cells Following 24 hours on the 3T3 feeder cells, cells were stimulated with CD3/CD28 beads added to the cultures at a 1 :3 bead: T cell ratio. Expansion of T cells was determined with trypan blue enumeration and fresh beads were added twice to the cultures (indicated by the arrows).
• 1928z-E27 cells continued to expand to greater levels compared to 1928z T cells when cultured with PDL1 + tumor cells (Figure 13C).
• Transduced T cells were stimulated with Nalm6-PDL1 tumor cells as shown in Figure 3C were re-stimulated with Nalm6-PDL1 tumor cells at the 1 :5 T E:T ratio. After 48 hours co-culture flow cytometry was used to determine lysis of tumor targets.
• 1928z-E27 retained ability to lyse PD-L1 tumor targets upon re-stimulation compared to 1928z cells (Figure 13D).
• PD-1 blocking mAb candidates E27, E26 and E23 were used in a competitive binding assay to detect interruption of PD-1 binding to PD-L1 at varying concentrations, compared to a control mAb, targeted to a hapten not present in humans.
• E23, E26 and E27 mAbs all prevented PD-1 binding to PD-L1 ( Figure 15A).
• T cells can be co-modified to express CAR and secrete PD-1 blocking scFv, E27.
• Figure 16A is a representative flow cytometry plot demonstrating equivalent CAR expression following transduction with the 1928z CAR alone (1928z) or the 1928z CAR and the E27 PD-1 blocking scFv (1928z-E27), following staining with 19E3 mAb that specifically binds the 1928z CAR.
• Figure 16B shows a Western blot on SN from 1928z and 1928z-E27 T cells stained with anti-HA mAb, showing only a ⁇ 30 kDa protein in the 1928z-E27 cells, demonstrating that the E27 scFv is secreted from the 1928z-E27 transduced T cells and not those transduced with the CAR alone.
• Figure 16C is a representative flow cytometry demonstrating lower levels of PD-1 expression on 1928z-E27 T cells compared to 1928z T cells following transduction. Expression of PD-1 was statistically significantly lower on 1928z- E27 T cells compared to 1928z T cells, data shown is mean +/- SEM from 4 independent experiments ( Figure 16D). A 4 hr 51 Cr release assay
• 1928z-E27 T cells lyse statistically significantly more Raji-PDL1 tumor cells compared to 1928z T cells, data shown the mean +/- SEM from 4 independent experiments ( Figure 17C).
• 1928z-E27 T cells expand to greater numbers following co-culture with Raji- PDL1 tumor cells as determined by flow cytometry and enumeration beads, data shown is the average total number of T cells +/- SEM from 4 independent experiments ( Figure 17D).
• Figure 17E shows a representative flow cytometry plot showing increased PD-1 expression on 1928z T cells compared to 1928z- E27 T cells following 7 days co-culture with Raji-PDL1 tumor cells.
• 1928z T cells express significantly more PD-1 compared to 1928z-E27 T cells, with regard to percentage positive cells and mean fluorescence intensity (MFI) of PD-1 staining. Data show in the mean +/- SEM from 4 independent
• Figure 17F shows representative flow cytometry plots showing increased percentage of 2B4+PD-1 + 1928z T cells compared to 1928z-E27 cells following coculture with Raji-PDL1 for 7 days.
• 1928z-E27 T cells also express less BTLA and TIM3 on the 2B4+PD-1 + population. Data shown is representative of 3 independent experiments.
• E27 protects proliferative capacity of CD3/CD28 stimulated T cells in the context of PD-L1.
• NIH3T3 cells were retrovirally modified to express human PD-L1 (3T3-PDL1 ) and were stained with mAb specific for PD-L1 .
• Parental NIH3T3 (3T3-EMPTY) express no PD-L1 and 3T3-PDL1 tumor cells expressed high levels of PD-L1 ( Figure 18A).
• 1928z and 1928z-E27 T cells were cultured with 3T3-EMPTY or 3T3-PDL1 cells and stimulated with
• CD3/CD28 beads Cells were enumerated and re-plated on new 3T3 cells on days 3, 6, 9 and 12.
• 1928z T cells had reduced expansion when cultured with 3T3-PDL1 cells compared to 3T3-EMPTY cells.
• 1928z-E27 cells had equivalent expansion when cultured on 3T3-EMPTY or 3T3-PDL1 cells
• Figure 18B Data shown is the mean fold expansion +/- SEM from 4 independent experiments.
• Figure 18C are representative flow cytometry plots showing increased expression of 2B4, PD-1 , BTLA and TIM3 on 1928z T cells cultured with 3T3-PDL1 compared to1928z T cells cultured on 3T3-EMPTY cells.
• 1928z-E27 cells had equivalent expression of 2B4, PD-1 , BTLA-4 and TIM3 when cultured with 3T3-EMPTY and 3T3-PDL1 .
• Data shown is representative of 3 independent experiments.
• CAR T cells secreting E27 scFv have increased anti-tumor function in vivo.
• SCID-Beige mice were inoculated with Raji-PDL1 tumor cells
• mice treated with 1928z-E27 T cells had enhanced survival compared to mice treated with 1928z T cells.
• Mice treated with 1928z T cells survived longer than untreated mice, and mice treated with CAR T cells targeted to an irrelevant antigen, 4H1 128z and 4H1 128z-E27 T cells. Data shown is from 2 independent experiments.
• ET901 (negative control) showed no binding, while ET130-23, ET130-26 and ET130-27 showed a blocking effect to PD1 /PDL2 binding over the same range of concentrations.
• ET130-26 showed the highest blocking effect against PD1/PDL2, while ET130-23 showed the lowest effect.
• the blocking pattern is parallel to PD1/PDL1 binding.
• the application of the anti-PD-1 scFvs or monoclonal antibodies is investigated for the ability of the scFvs or monoclonal antibodies to dampen the immune response and subvert autoimmune diseases.
• This can also be investigated using murine models of GVHD.
• T cells secreting an anti-PD-1 scFv (or T cells augmented with injection of monoclonal antibodies) are infused into a subject and the development of GVHD is assessed.
• the anti-PD-1 scFv/mAb is agonistic, the GVHD response is inhibited due to suppression of the human T cells.
• a recombinant antigen-binding protein or antigen-binding fragment thereof comprising one of:
• (A) an antigen binding region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID N O: 21 , SEQ ID NO: 32, SEQ ID NO: 43, SEQ ID NO: 53, SEQ ID NO: 61 , SEQ ID NO: 72, SEQ ID NO: 83, SEQ ID NO: 94, SEQ ID NO: 103, SEQ ID N O: 1 14, SEQ ID NO: 125, SEQ ID NO: 133, SEQ ID NO: 142; a fragment thereof and a homologous sequence thereof;
• (B) an antigen binding region comprising a variable light chain (VL) and variable heavy chain (VH), respectively, with amino acid sequences selected from SEQ ID NOS: 6 and 8; SEQ ID NOS: 17 and 19; SEQ ID NOS: 28 and 30; SEQ ID NOS: 39 and 41 ; SEQ ID NOS: 49 and 51 ; SEQ ID NOS: 57 and 59; SEQ ID NOS: 68 and 70; SEQ ID NOS: 79 and 81 ; SEQ ID NOS: 90 and 92; SEQ ID NOS: 99 and 101 ; SEQ ID NOS: 1 10 and 1 12; SEQ ID NOS: 121 and 123; SEQ ID NOS: 129 and 131 ; SEQ ID NOS: 138 and 140; fragments thereof and homologous sequences thereof;
• LC light chain
• LCCDR light chain complementarity determining regions
• HC heavy chain
• HCCDR heavy chain complementarity determining regions
• a light chain (LC) comprising LCCDR1 , LCCDR2 and LCCDR3 respectively, having the amino acid sequence SSNIGAGYA (SEQ ID NO: 12), TNN and QSYDSSLSGVI (SEQ ID NO: 13) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GYTLTELS (SEQ ID NO: 14), FDPEDGET (SEQ ID NO. 15) and ARAYYGFDQ (SEQ ID NO: 16); fragments thereof and homologous sequences thereof; (iii) a light chain (LC) comprising LCCDR1 , LCCDR2 and LCCDR3
• LC light chain
• ARWYSSYYDV (SEQ ID NO: 38); fragments thereof and homologous sequences thereof;
• LC light chain
• NIGSKS amino acid sequence NIGSKS (SEQ ID NO: 34), YDS and QVWDSSSDYV (SEQ ID NO: 45) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), ISGSGGST (SEQ ID NO. 47) and
• ARNYISMFDS SEQ ID NO: 48; fragments thereof and homologous sequences thereof;
• LC light chain
• NIGSKS amino acid sequence NIGSKS (SEQ ID NO: 34), YDS and QVWDSSSDHV (SEQ ID NO: 55) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), ISGSGGST (SEQ ID NO. 47) and ARGYSSYYDA (SEQ ID NO: 56); fragments thereof and homologous sequences thereof;
• LC light chain
• a light chain comprising LCCDR1 , LCCDR2 and LCCDR3 respectively, having the amino acid sequence RSNIGSNT (SEQ ID NO: 74), NNN and ATWDDSLNEYV (SEQ ID NO: 75) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GYTFTRYG (SEQ ID NO: 76), ISGYNGNT (SEQ ID NO. 77) and ARHGYGYHGD (SEQ ID NO: 78); fragments thereof and homologous sequences thereof;
• LC light chain
• LC light chain
• NIGDKS amino acid sequence 96
• YDS and QVWASGTDHPYVI amino acid sequence 97
• HC heavy chain comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), ISGSGGST (SEQ ID NO. 47) and
• ARMYGSYTDM (SEQ ID NO: 98); fragments thereof and homologous sequences thereof;
• LC light chain
• LC light chain
• ARGDVTYDE (SEQ ID NO: 120); fragments thereof and homologous sequences thereof;
• LC light chain
• HC heavy chain
• ARSQASFMDI (SEQ ID NO: 128); fragments thereof and homologous sequences thereof; or (xiv) a light chain (LC) comprising LCCDR1 , LCCDR2 and LCCDR3 respectively, having the amino acid sequence NIGSKS (SEQ ID NO: 34), DDS and QVWDSSSDQGV (SEQ ID NO: 135) and a heavy chain (HC) comprising HCCDR1 , HCCDR2 and HCCDR3 respectively, having amino acid sequences GFTFSSYA (SEQ ID NO: 46), IGTGGGT (SEQ ID NO. 136) and
• ARGTGYDGDQ (SEQ ID NO: 137); fragments thereof and homologous sequences thereof.
• antigen-binding protein of embodiment 1 wherein said antigen-binding protein is a chimeric antigen receptor (CAR).
• CAR chimeric antigen receptor
• a cell comprising an antigen-binding protein of any one of embodiments 1 -7, a nucleic acid of embodiment 8 or a vector of embodiment 9.
• antigen-binding protein of embodiment 1 1 wherein said therapeutic agent is a drug, toxin, radioisotope, protein, or peptide.
• a pharmaceutical composition comprising an antigen-binding protein of any one of embodiments 1 -7, a nucleic acid of embodiment 8, a vector of embodiment 9, a cell of embodiment 10 or an antigen-binding protein of embodiment 1 1 or 12.
• composition of embodiment 13 further comprising a pharmaceutically acceptable carrier.
• a method of increasing a T cell response in a subject comprising administering to the subject a therapeutically effective amount of an antigen- binding protein or an antigen binding fragment thereof of any one of embodiments 1 -7, a nucleic acid of embodiment 8, a vector of embodiment 9, a cell of embodiment 10, an antigen-binding protein of either of embodiments 1 1 or 12 or a pharmaceutical composition of either of embodiments 13 or 14. 16.
• a method for treatment of a subject having a PD1 -positive disease comprising administering to the subject a therapeutically effective amount of an antigen-binding protein or antigen binding fragment thereof of any one of embodiments 1 -7, a nucleic acid of embodiment 8, a vector of embodiment 9, a cell of embodiment 10, an antigen-binding protein of either of embodiments 1 1 or 12 or a pharmaceutical composition of either of
• embodiment 21 The use of embodiment 20, wherein the PD1 -positive disease is a cancer.
• 22 Use of a recombinant anti-PD1 antigen-binding protein or antigen-binding fragment thereof of any one of embodiments 1 -7, a nucleic acid of embodiment 8, a vector of embodiment 9, a cell of embodiment 10, an antigen-binding protein of either of embodiments 1 1 or 12 or a pharmaceutical composition of either of embodiments 13 or 14 for immunomodulation by inhibiting the PD-1 signaling pathway.
• a vector comprising a nucleic acid encoding a recombinant anti- PD-1 antigen-binding protein and a nucleic acid encoding a chimeric antigen receptor, wherein said recombinant anti-PD-1 antigen-binding protein is not identical to said chimeric antigen receptor.
• a cell comprising the vector of embodiment 23.
• a cell comprising a nucleic acid encoding a recombinant anti-PD- 1 antigen-binding protein and a nucleic acid encoding a chimeric antigen receptor, wherein said recombinant anti-PD-1 antigen-binding protein is not identical to said chimeric antigen receptor.
• a cell comprising a recombinant anti-PD-1 antigen-binding protein and a chimeric antigen receptor, wherein said recombinant anti-PD-1 antigen-binding protein is not identical to said chimeric antigen receptor.
• T cell 38.
• a pharmaceutical composition comprising a vector or a cell of any one of embodiments 23-37.
• composition of embodiment 38 further comprising a pharmaceutically acceptable carrier.
• a method of increasing a T cell response in a subject comprising administering to the subject a therapeutically effective amount of a vector or cell of any one of embodiments 23-37, or a pharmaceutical composition of embodiment 38 or 39, wherein the recombinant anti-PD-1 antigen-binding protein is a PD-1 antagonist.
• a method of decreasing a T cell response in a subject comprising administering to the subject a therapeutically effective amount of a vector or cell of any one of embodiments 23-37, or a pharmaceutical composition of embodiment 38 or 39, wherein the recombinant anti-PD-1 antigen-binding protein is a PD-1 agonist.
• a method for treatment of a subject having a PD1 -positive disease comprising administering to the subject a therapeutically effective amount of a vector or cell of any one of embodiments 23-37, or a
• a method for treatment of a subject having a PD1 -positive disease comprising transducing at least one T cell of the subject with a nucleic acid encoding a recombinant anti-PD-1 antigen-binding protein and a nucleic acid encoding a chimeric antigen receptor, wherein said recombinant anti-PD-1 antigen-binding protein is not identical to said chimeric antigen receptor.
• an antigen-binding protein of embodiment 5 a vector or cell of any one of embodiments 23-37, or a pharmaceutical composition of embodiment 38 or 39, wherein the recombinant anti-PD-1 antigen-binding protein is a PD-1 agonist, for the treatment of an autoimmune disease.
• therapeutic agent is a drug, toxin, radioisotope, protein, or peptide.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Zoology (AREA)
• Biomedical Technology (AREA)
• Cell Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• Pharmacology & Pharmacy (AREA)
• Gastroenterology & Hepatology (AREA)
• Wood Science & Technology (AREA)
• Toxicology (AREA)
• Microbiology (AREA)
• Hematology (AREA)
• General Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Mycology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (9)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=56373127

Family Applications (1)

Country Status (11)

Cited By (32)

Families Citing this family (21)

Citations (1)

Family Cites Families (18)

• 2016
  • 2016-06-23 HK HK18113888.8A patent/HK1254803A1/zh unknown
  • 2016-06-23 WO PCT/US2016/039015 patent/WO2016210129A1/en not_active Ceased
  • 2016-06-23 EP EP16736667.3A patent/EP3313883B1/en active Active
  • 2016-06-23 CN CN201680037151.1A patent/CN108337890B/zh active Active
  • 2016-06-23 CA CA3006224A patent/CA3006224A1/en not_active Abandoned
  • 2016-06-23 JP JP2018519261A patent/JP6974311B2/ja active Active
  • 2016-06-23 AU AU2016281641A patent/AU2016281641B2/en active Active
  • 2016-06-23 KR KR1020187002014A patent/KR20180019725A/ko not_active Withdrawn
  • 2016-06-23 CN CN202111160281.3A patent/CN114133448A/zh active Pending
  • 2016-06-23 TW TW105119709A patent/TWI773647B/zh not_active IP Right Cessation
• 2017
  • 2017-12-20 US US15/849,107 patent/US11136392B2/en active Active
  • 2017-12-20 IL IL256463A patent/IL256463A/en unknown
• 2021
  • 2021-07-16 JP JP2021117516A patent/JP2021177768A/ja not_active Ceased

Patent Citations (1)

Non-Patent Citations (25)

Also Published As

Similar Documents

Legal Events